HAS1 and cancer: In this study, to determine the importance of HA/CD44 in TGF-β1-induced EGF signaling activation and EMT in cancer cells, we used the HAS inhibitor, 4-MU, to block HAS expression and shRNA targeting CD44 to knockdown CD44 expression.